Do analysts prefer PASG or XBIT?

Passage Bio currently has a consensus price target of $13.25, suggesting a potential upside of 142.23%. Given Passage Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Passage Bio is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Passage Bio 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, PASG or XBIT?

XBiotech is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.84 N/A XBiotech N/A N/A -$45.54M -$1.32 N/A

Is PASG or XBIT more profitable?

XBiotech's return on equity of -26.10% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% XBiotech N/A -26.10% -25.06%

Which has preferable valuation & earnings, CTOR or PASG?

Citius Oncology is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Oncology N/A N/A -$24.76M -$0.47 N/A Passage Bio N/A N/A -$45.52M -$11.84 N/A

Is CTOR or PASG more profitable?

Citius Oncology's return on equity of -99.47% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -99.47% -42.16% Passage Bio N/A -150.88% -59.78%

Is PASG or MCRB more profitable?

Seres Therapeutics' return on equity of -130.29% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% Seres Therapeutics N/A -130.29% -35.35%

Do analysts prefer TCRT or PASG?

Passage Bio has a consensus target price of $13.25, indicating a potential upside of 142.23%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts clearly believe Passage Bio is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Passage Bio 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14

Which has better earnings and valuation, TCRT or PASG?

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A Passage Bio N/A N/A -$45.52M -$11.84 N/A

Is TCRT or PASG more profitable?

Passage Bio's return on equity of -150.88% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -165.94% -123.50% Passage Bio N/A -150.88% -59.78%

Passage Bio (PASG) Competitors

$5.47 -0.15 (-2.67%)

Closing price 04:00 PM Eastern

Extended Trading

$5.42 -0.05 (-1.01%)

As of 05:35 PM Eastern

Compare

PASG vs. XBIT, CTOR, MCRB, TCRX, and TCRT

Should you buy Passage Bio stock or one of its competitors? MarketBeat compares Passage Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Passage Bio include XBiotech (XBIT), Citius Oncology (CTOR), Seres Therapeutics (MCRB), TScan Therapeutics (TCRX), and Alaunos Therapeutics (TCRT). These companies are all part of the "pharmaceutical products" industry.

How does Passage Bio compare to XBiotech?

Passage Bio (NASDAQ:PASG) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

XBiotech is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 4.9% of Passage Bio shares are held by company insiders. Comparatively, 30.8% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

XBiotech's return on equity of -26.10% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
XBiotech	N/A	-26.10%	-25.06%

In the previous week, Passage Bio's average media sentiment score of 0.00 equaled XBiotech'saverage media sentiment score.

Company	Overall Sentiment
Passage Bio	Neutral
XBiotech	Neutral

Passage Bio currently has a consensus price target of $13.25, suggesting a potential upside of 142.23%. Given Passage Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Passage Bio is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Passage Bio has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

Summary

Passage Bio beats XBiotech on 6 of the 11 factors compared between the two stocks.

How does Passage Bio compare to Citius Oncology?

Citius Oncology (NASDAQ:CTOR) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Citius Oncology's return on equity of -99.47% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Passage Bio	N/A	-150.88%	-59.78%

Citius Oncology currently has a consensus price target of $6.00, suggesting a potential upside of 650.09%. Passage Bio has a consensus price target of $13.25, suggesting a potential upside of 142.23%. Given Citius Oncology's stronger consensus rating and higher probable upside, research analysts clearly believe Citius Oncology is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Citius Oncology is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

In the previous week, Citius Oncology had 1 more articles in the media than Passage Bio. MarketBeat recorded 1 mentions for Citius Oncology and 0 mentions for Passage Bio. Citius Oncology's average media sentiment score of 0.25 beat Passage Bio's score of 0.00 indicating that Citius Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Citius Oncology	Neutral
Passage Bio	Neutral

Citius Oncology has a beta of 3.42, indicating that its stock price is 242% more volatile than the broader market. Comparatively, Passage Bio has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by insiders. Comparatively, 4.9% of Passage Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Citius Oncology beats Passage Bio on 11 of the 12 factors compared between the two stocks.

How does Passage Bio compare to Seres Therapeutics?

Passage Bio (NASDAQ:PASG) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Passage Bio presently has a consensus price target of $13.25, indicating a potential upside of 142.23%. Seres Therapeutics has a consensus price target of $22.00, indicating a potential upside of 250.32%. Given Seres Therapeutics' higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Passage Bio has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market.

Seres Therapeutics' return on equity of -130.29% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Seres Therapeutics	N/A	-130.29%	-35.35%

In the previous week, Seres Therapeutics had 4 more articles in the media than Passage Bio. MarketBeat recorded 4 mentions for Seres Therapeutics and 0 mentions for Passage Bio. Seres Therapeutics' average media sentiment score of 0.81 beat Passage Bio's score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Passage Bio	Neutral
Seres Therapeutics	Positive

Seres Therapeutics has higher revenue and earnings than Passage Bio. Seres Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
Seres Therapeutics	$790K	76.95	$5.70M	-$5.17	N/A

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 4.9% of Passage Bio shares are held by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Seres Therapeutics beats Passage Bio on 10 of the 14 factors compared between the two stocks.

How does Passage Bio compare to TScan Therapeutics?

Passage Bio (NASDAQ:PASG) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Passage Bio currently has a consensus target price of $13.25, suggesting a potential upside of 142.23%. TScan Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 503.68%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, TScan Therapeutics had 2 more articles in the media than Passage Bio. MarketBeat recorded 2 mentions for TScan Therapeutics and 0 mentions for Passage Bio. TScan Therapeutics' average media sentiment score of 0.84 beat Passage Bio's score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Passage Bio	Neutral
TScan Therapeutics	Positive

Passage Bio has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. TScan Therapeutics' return on equity of -91.94% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Passage Bio has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

Passage Bio has higher earnings, but lower revenue than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
TScan Therapeutics	$10.32M	6.29	-$129.77M	-$0.96	N/A

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 4.9% of Passage Bio shares are held by insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

TScan Therapeutics beats Passage Bio on 11 of the 15 factors compared between the two stocks.

How does Passage Bio compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

Passage Bio's return on equity of -150.88% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Passage Bio	N/A	-150.88%	-59.78%

Alaunos Therapeutics has a beta of -1.07, meaning that its share price is 207% less volatile than the broader market. Comparatively, Passage Bio has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

Passage Bio has a consensus target price of $13.25, indicating a potential upside of 142.23%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts clearly believe Passage Bio is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 4.9% of Passage Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

In the previous week, Alaunos Therapeutics' average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score.

Company	Overall Sentiment
Alaunos Therapeutics	Neutral
Passage Bio	Neutral

Summary

Passage Bio beats Alaunos Therapeutics on 8 of the 11 factors compared between the two stocks.

Get Passage Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PASG vs. The Competition

Export

Metric	Passage Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.03M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-0.46	18.61	23.92	23.74
Price / Sales	N/A	298.43	507.57	108.00
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	0.93	8.04	10.28	6.78
Net Income	-$45.52M	$23.89M	$3.57B	$337.51M
7 Day Performance	-6.50%	-5.97%	-1.43%	-2.72%
1 Month Performance	29.93%	2.78%	3.27%	1.87%
1 Year Performance	-35.31%	36.26%	23.37%	26.60%

Passage Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PASG Passage Bio	2.3353 of 5 stars	$5.47 -2.7%	$13.25 +142.2%	-33.5%	$18.03M	N/A	N/A	130
XBIT XBiotech	0.3556 of 5 stars	$2.37 -2.1%	N/A	-18.3%	$73.78M	N/A	N/A	100	High Trading Volume
CTOR Citius Oncology	2.0437 of 5 stars	$0.79 -1.5%	$6.00 +663.4%	-25.7%	$73.67M	$5.61M	N/A	N/A
MCRB Seres Therapeutics	2.088 of 5 stars	$7.45 +1.8%	$22.00 +195.3%	-19.4%	$70.89M	$1.15M	N/A	330	Analyst Upgrade
TCRX TScan Therapeutics	3.1378 of 5 stars	$0.98 -9.6%	$6.00 +514.8%	-45.5%	$70.58M	$10.32M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PASG) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Passage Bio (PASG) Competitors

PASG vs. XBIT, CTOR, MCRB, TCRX, and TCRT

How does Passage Bio compare to XBiotech?

Summary

How does Passage Bio compare to Citius Oncology?

Summary

How does Passage Bio compare to Seres Therapeutics?

Summary

How does Passage Bio compare to TScan Therapeutics?

Summary

How does Passage Bio compare to Alaunos Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Passage Bio (PASG) Competitors

PASG vs. XBIT, CTOR, MCRB, TCRX, and TCRT

How does Passage Bio compare to XBiotech?

Which has stronger valuation and earnings, PASG or XBIT?

Do institutionals and insiders hold more shares of PASG or XBIT?

Is PASG or XBIT more profitable?

Does the media refer more to PASG or XBIT?

Do analysts prefer PASG or XBIT?

Which has more volatility and risk, PASG or XBIT?

Summary

How does Passage Bio compare to Citius Oncology?

Is CTOR or PASG more profitable?

Do analysts prefer CTOR or PASG?

Which has preferable valuation & earnings, CTOR or PASG?

Does the media prefer CTOR or PASG?

Which has more volatility and risk, CTOR or PASG?

Do institutionals and insiders hold more shares of CTOR or PASG?

Summary

How does Passage Bio compare to Seres Therapeutics?

Do analysts recommend PASG or MCRB?

Which has more risk and volatility, PASG or MCRB?

Is PASG or MCRB more profitable?

Does the media favor PASG or MCRB?

Which has higher valuation and earnings, PASG or MCRB?

Do institutionals and insiders hold more shares of PASG or MCRB?

Summary

How does Passage Bio compare to TScan Therapeutics?

Do analysts prefer PASG or TCRX?

Does the media refer more to PASG or TCRX?

Is PASG or TCRX more profitable?

Which has more volatility & risk, PASG or TCRX?

Which has better earnings and valuation, PASG or TCRX?

Do institutionals and insiders hold more shares of PASG or TCRX?

Summary

How does Passage Bio compare to Alaunos Therapeutics?

Is TCRT or PASG more profitable?

Which has more volatility & risk, TCRT or PASG?

Do analysts prefer TCRT or PASG?

Do insiders & institutionals believe in TCRT or PASG?

Which has better earnings and valuation, TCRT or PASG?

Does the media prefer TCRT or PASG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools